Spring background with fresh green leaves.
Our Work

Latham & Watkins Advises Leading Biomaterials Company Bolt Threads, Inc. in Definitive Business Combination Agreement With Golden Arrow Merger Corp.

October 5, 2023
Firm represents Bolt Threads in concurrent financing, PIPE, and SPAC deal that thrusts the biomaterials industry forward.

Bolt Threads, Inc. (Bolt Threads), a pioneer in sustainable biomaterials for consumer products, announced a definitive agreement for a business combination with Golden Arrow Merger Corp. (Nasdaq: GAMC) (Golden Arrow) that would result in Bolt Threads becoming a public company. The combined company will be named “Bolt Projects Holdings, Inc.” and is expected to remain listed on the Nasdaq under a new ticker symbol “BSLK.” Concurrent financing transactions expected to provide at least US$35 million of gross proceeds to the company, including fully committed common stock PIPE of up to US$28 million at US$10.00 per share anchored by Bolt Threads’ existing investors — including Baillie Gifford, Temasek, Top Tier, Founders Fund, Formation 8, Foundation Capital, and Golden Arrow Sponsor, LLC.

Latham & Watkins represents Bolt Threads in the deal with a transactional team led by partners Jim Morrone, Drew Capurro, Haim Zaltzman, with associates Nima Movahedi, Tiana Baghdikian, Shannon Cheng, Erik Jensen, Danny Del Giorno, Jacob Walsh, Courtney Lem, Viva Jerónimo, and Erica Kucharski; on debt finance matters by partner Dan Van Fleet, with associate Hyunji Lee; on benefits matters by partner Julie Crisp; on tax matters by partner Katharine Moir, and associate Gregory Conyers; on IP and data privacy matters by partner Michelle Gross, and associates Adriana Beach and Caroline Omotayo; on HSR matters by partner Joshua Holian, and counsel Joseph Simei; and on trade controls / sanctions matters by counsel Andrew Galdes.